FISCAL YEAR 2006
Nancy J. Norton, President and Founder of IFFGD presented the following testimony regarding Fiscal Year 2006 Funding for Functional Gastrointestinal and Motility Disorders Research before the House Appropriations Subcommittee on Labor, Health & Human Services, Education and Related Agencies in 2005: Chairman Regula and members of the Subcommittee, thank you for the opportunity to present […]
FISCAL YEAR 2005
Nancy J. Norton, President and Founder of IFFGD presented the following testimony regarding Fiscal Year 2005 Funding for Functional Gastrointestinal and Motility Disorders Research to the House Appropriations subcommittee on Labor, Health & Human Services, Education and Related Agencies in 2004: Chairman Regula and members of the Subcommittee, thank you for the opportunity to present […]
FISCAL YEAR 2003
On May 2, 2002 IFFGD Founder and President Nancy J. Norton presented the following testimony regarding Fiscal Year 2003 Irritable Bowel Syndrome Research to the House Appropriations Subcommittee on Labor, Health & Human Services, Education and Related Agencies: Chairman Regula and members of the Subcommittee, thank you for the opportunity to present this written statement […]
Testimony to FDA April 23, 2002
On April 23, 2002, IFFGD Founder and President, Nancy J. Norton presented the following testimony on behalf of IFFGD members to the Center for Drug Evaluation and Research, Gastrointestinal Drugs Advisory Committee regarding risk management for (NDA)21-107, LOTRONEX (alosetron), produced by GlaxoSmithKline: Mister Chairman, I would like to thank the Advisory Committee for the opportunity […]
Comments to FDA November 9, 2000
IFFGD sent the following written comments to the FDA in connection with a November 9, 2000 meeting of the Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee to discuss Lotronex: Recent attention has focused on the new drug, Lotronex, for the treatment of Irritable Bowel Syndrome (IBS) symptoms in women who suffer from IBS-associated […]
Testimony to FDA June 27, 2000
IFFGD Founder and President Nancy Norton presented the following testimony on behalf of IFFGD members at a June 27, 2000 Center for Drug Evaluation and Research, Gastrointestinal Drugs Advisory Committee meeting on NDA 21-107, LOTRONEX (alosetron): Thank you, Members of the Committee. I hope you are not going to be tired of hearing from me […]
Testimony to FDA June 26, 2000
On June 26, 2000, IFFGD Founder and President Nancy J. Norton presented the following testimony on behalf of IFFGD members to the Center for Drug Evaluation and Research, Gastrointestinal Drugs Advisory Committee regarding (NDA) 21-200, Zelnorm/Zelmac (tegaserod), produced by Novartis Pharmaceuticals Corporation: Before I begin, I would just like to say that I am here […]
